Skip to content
lifestyle.militaryparenting.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Edgewise Therapeutics, Inc.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
June 16, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
June 3, 2026
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
May 12, 2026
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
May 7, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
May 4, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
April 1, 2026